Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K’s NICE To Help Build India’s Health Technology Assessment Board

This article was originally published in PharmAsia News

Executive Summary

India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.

You may also be interested in...



NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

Erbitux and Avastin Aren’t Cost Effective, NICE Finds

Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC084644

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel